TLC completes enrollment for Phase 2 TLC590 study before schedule
Date: 2020-02-14   Author: Saipriya Iyer  Category: #news

TLC completes enrollment for Phase 2 TLC590 study before schedule

TLC recently announced that the patient enrollment in TLC590’s Part 2 of Phase II clinical trial has been completed earlier than it was originally scheduled, which is being performed at four sites across the United States.

For the record, TLC590 is essentially a non-opioid, proprietary BioSeizer that has a sustained ropivacaine release formulation aimed at managing post-surgical pain with a single dose for more than three days. This could potentially reduce the need to take opioids after surgery.

The double-blind, placebo-controlled, randomized and comparator study will be assessing TLC590’s analgesic safety and efficacy for the management of postsurgical pain in patients after bunionectomy. The topline data will be reported sometime in the middle of 2020.

Apparently, after bunionectomy, the dose linearity, relative bioavailability and safety of TLC590 in Part 1 out of the two Phase II clinical trial were recognized based on about 50 patients.

While in a safety and efficacy study of Part 2, nearly 150 patients are randomized at 1:1:1 ratio so that they take TLC590 228 mg single infiltrative local dose, a normal saline placebo or bupivacaine 50mg by the end of their bunionectomy surgery.

The patients are closely monitored for a period of 72 hours and are further followed up for 42 days post-surgery. The area under the curve (AUC) has been considered as the key endpoint ranging from 0-72 hours based on pain rating scales in numbers. The secondary endpoints depict a proportion of patients who are opioid-free and pain-free as well as the total consumption of opioid post-surgery at several time periods and the use of opioids the first time after the operation.

TLC President, George Yeh stated that the data from the previous Phase I/II trial after hernia surgeries, as well as if the current Phase II trial turn out to be positive, it will give the company the confidence to proceed into Phase III trials.

 

Source Credit- https://www.streetinsider.com/Corporate+News/TLC+%28TLC%29+Reports+Early+Completion+of+Patient+Enrollment+in+TLC590+Phase+II+Clinical+Trial+following+Bunionectomy/16453079.html



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Rotary Scroll Air Compressor Market is set to record 3% CAGR during forecast time
Author: Rahul Varpe

The size of the Rotary Scroll Air Compressor Market was accrued at USD 4.6 billion in 2018 and is presumed to accumulate over USD 5.5 billion by the year 2024. According to research, the Rotary Scroll Air Compressor Market is expected to grow with...


By 2025, Building Thermal Insulation Market is Expected to Grow at a CAGR of 4.5%
Author: Rahul Varpe

The Building Thermal Insulation Market size was estimated at USD 25 billion in 2018 and is projected to surpass USD 35 billion by the year 2025.

During the period of 2019-2025, the Building Thermal Insulation Market is anticipated to exp...


U.S. Residential Furnace Market Research Report to 2025 | Growth Study by Application & Product
Author: Rahul Varpe

The U.S. Residential Furnace Market is projected to expand from its present industry value of over $115 billion to more than $200 billion over the analysis timeframe.

According to the study with title ‘U.S. Residential Furnace Mark...